Skip to main content
    L

    Lantern Pharma Inc (LTRN)

    Official site

    HEALTHCARE • BIOTECHNOLOGY • NASDAQ

    $0.39
    -0.04 (-10.18%)

    Market Cap: $6.47M

    Last updated: Nov 17, 2026 at 11:01 AM ET

    Lantern Pharma Inc (LTRN) Competitors

    Updated Nov 17, 2026. Similar companies are ranked by business profile, size, sector and industry; metrics come from company filings and market prices.

    The companies most similar to Lantern Pharma are Liminatus Pharma, Inc. Class A Common Stock (LIMN), CNS Pharmaceuticals (CNSP) and Processa Pharmaceuticals (PCSA). By market cap, Lantern Pharma ranks 7th of the 13 companies on this page; Tscan Therapeutics (TCRX) is the largest at $10.89M.

    Peer Comparison

    LTRN's revenue growth of 0.0% is in line with the peer median. Like the median peer, it pays no dividend.

    CompanyMarket capP/EP/SNet marginROICRev growthDiv yield
    Lantern Pharma (LTRN)$6.47MN/AN/A0.0%N/A0.0%0.00%
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)$4.02MN/AN/A0.0%-247.2%0.0%0.00%
    CNS Pharmaceuticals Inc (CNSP)$4.22MN/AN/A0.0%N/A0.0%0.00%
    Processa Pharmaceuticals Inc (PCSA)$5.20MN/AN/A0.0%N/A0.0%0.00%
    Tempest Therapeutics Inc (TPST)$7.64MN/AN/A0.0%-783.6%0.0%0.00%
    Traws Pharma Inc (TRAW)$3.86MN/AN/A0.0%N/A-100.0%0.00%
    Alaunos Therapeutics Inc (TCRT)$6.86MN/AN/A0.0%N/A-25.0%0.00%
    PharmaCyte Biotech Inc (PMCB)$3.77MN/AN/A0.0%N/A0.0%0.00%
    GT Biopharma Inc (GTBP)$7.67MN/AN/A0.0%N/A0.0%0.00%
    Aprea Therapeutics Inc (APRE)$5.91MN/AN/A0.0%N/A-98.4%0.00%
    Tscan Therapeutics Inc (TCRX)$10.89MN/A3.6x0.0%-129.7%-65.8%0.00%
    Moleculin Biotech Inc (MBRX)$8.02MN/AN/A0.0%N/A0.0%0.00%
    Longeveron LLC (LGVN)$8.40MN/A5.9x0.0%N/A-9.2%0.00%
    Peer median$6.38MN/A4.8x0.0%-247.2%0.0%0.00%
    Market data as of Nov 17, 2026. Net margin covers the trailing 12 months, Rev growth compares the latest quarter with a year earlier and Div yield is the forward yield. P/E uses earnings per share for the last 12 months as companies report it, often adjusted, so it can show beside a negative net margin, which uses net income. P/E and P/S show N/A when those earnings or sales are negative or missing, or the multiple is above 1,000x.

    Similar Companies

    These are the 12 companies most similar to Lantern Pharma, ranked by how closely their business, size, sector and industry match. All 12 are in one industry, Biotechnology.

    CompanyAboutPeers
    Liminatus Pharma, Inc. Class A Common Stock (LIMN)
    Liminatus Pharma, Inc. is a clinical-stage immuno-oncology company that develops novel cancer therapies. The company is headquartered in LA Palma, California.
    LIMN competitors
    CNS Pharmaceuticals Inc (CNSP)
    CNS Pharmaceuticals, Inc., a clinical pharmaceutical company, is dedicated to the development of cancer drug candidates for the treatment of brain and central...
    CNSP competitors
    Processa Pharmaceuticals Inc (PCSA)
    Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of pharmaceutical products for the treatment of patients...
    PCSA competitors
    Tempest Therapeutics Inc (TPST)
    Tempest Therapeutics Inc., a clinical-stage oncology company, is dedicated to the development of small molecules that combine targeted and immune-mediated...
    TPST competitors
    Traws Pharma Inc (TRAW)
    Traws Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on discovering and developing novel products to treat cancer in the United States.
    TRAW competitors
    Alaunos Therapeutics Inc (TCRT)
    Alaunos Therapeutics, Inc., a clinical-stage biopharmaceutical company, is focused on discovering, acquiring...
    TCRT competitors
    PharmaCyte Biotech Inc (PMCB)
    PharmaCyte Biotech, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing cell therapies for cancer and diabetes in the United...
    PMCB competitors
    GT Biopharma Inc (GTBP)
    GT Biopharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of immuno-oncology products based on its...
    GTBP competitors
    Aprea Therapeutics Inc (APRE)
    Aprea Therapeutics, Inc., a clinical-stage biopharmaceutical company, develops and markets cancer therapies that reactivate the mutant p53 tumor suppressor...
    APRE competitors
    Tscan Therapeutics Inc (TCRX)
    Tscan Therapeutics Inc (TCRX) is a pioneering clinical-stage biotechnology company specializing in precision oncology through its proprietary T cell receptor...
    TCRX competitors
    Moleculin Biotech Inc (MBRX)
    Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of cancer drug candidates for the treatment of highly resistant...
    MBRX competitors
    Longeveron LLC (LGVN)
    Longeveron Inc., a clinical-stage biotechnology company, is dedicated to developing cell therapies for life-threatening and aging-related conditions.
    LGVN competitors

    Frequently Asked Questions About LTRN

    Who are Lantern Pharma's main competitors?

    The companies most similar to Lantern Pharma include Liminatus Pharma, Inc. Class A Common Stock (LIMN), CNS Pharmaceuticals (CNSP), Processa Pharmaceuticals (PCSA), Tempest Therapeutics (TPST) and Traws Pharma (TRAW), listed from the closest match.

    Who is Lantern Pharma's biggest competitor?

    Tscan Therapeutics (TCRX) is the largest of the similar companies at $10.89M; Liminatus Pharma, Inc. Class A Common Stock (LIMN) is the closest match by business profile, size, sector and industry.

    How does LTRN stock compare with its competitors?

    LTRN's net margin is 0.0% against a peer median of 0.0%.

    Which of Lantern Pharma's competitors pays a higher dividend?

    Lantern Pharma pays no dividend. None of the similar companies with available yields has a higher forward dividend yield.

    Is Lantern Pharma bigger than its competitors?

    No. Lantern Pharma is 7th by market cap among the 13 companies on this page; the largest is Tscan Therapeutics (TCRX) at $10.89M.